This week members of the Global NASH Council and Global Liver Council will be sharing 11 research presentations at the International Liver Congress 2024 in Milan, Italy. Also, members pf GNC are actively participating as faculty in different scientific programs of ILC 2024.
- Cost of inaction for metabolic dysfunction-associated steatohepatitis (MASH): the projected economic burden in the United States, Zobair M Younossi, Jeffrey V. Lazarus, Alina M. Allen, Kenneth Cusi, Frank Tacke, Michael Roden, Jorn M. Schattenberg, Henry E. Mark, Linda Henry, Fatema Nader, James Paik.
- Prevalence and mortality of the spectrum of steatotic liver disease (SLD) in the US populations, Zobair M Younossi, Linda Henry, Pegah Golabi, Leyla de Avila, Ryuki Hashida, James Minhui Paik.
- Association of Quantitative Hepatic Collagen with Non-Invasive Tests (NITs) for Fibrosis in Patients with Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD), Zobair M Younossi, James M. Estep, Sean C. Felix, Brian P. Lam, Daisong Tan, Aaron B. Koenig, Fanny Monge, Andrei Racila, Zachary Goodman, Maria Stepanova.
- Association of non-invasive tests (NITs) with genetic polymorphism in patients with metabolic dysfunction–associated steatotic liver disease (MASLD), Zobair M Younossi, James M. Estep, Zohal Zekrya, Sean C. Felix, Brian P. Lam, Zaid Younossi, Andrei Racila, Maria Stepanova.
- Food swamps and easy access to unhealthy food increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) mortality in the United States (U.S.), Annette Paik, Linda Henry, Leyla de Avila, Saleh Alqahtani, Fatema Nader, James Minhui Paik, Zobair M Younossi.
- Associations of food insecurity and healthcare access with the prevalence and mortality of metabolic dysfunction-associated steatotic liver disease (MASLD): a global study of the United Nation and the global burden of disease data, Zobair M Younossi, Shira Zelber-Sagi, Carina Kugelmas, Jeffrey V. Lazarus, Annette Paik, Leyla de Avila, Lynn Gerber, James Minhui Paik
- Health-Related Quality of Life (HRQL) assessments in a 52-Week, double-blind, randomized, placebo-controlled phase 3 study of Resmetirom (MGL-3196) in patients with nonalcoholic steatohepatitis (NASH) and fibrosis (MAESTRO-NASH), Zobair M Younossi, Maria Stepanova, Andrei Racila, Linda Henry, Keith Miller, Dominic Labriola, Rebecca A Taub, Fatema Nader.
- Fatigue is an Important Driver of Work Productivity Loss and Impairment of Patient-Reported Outcomes (PROs) among Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Zobair M Younossi, Yusuf Yilmaz, Ming-Lung Yu, Vasily Isakov, Marlen Castellanos-Fernandez, Vincent Wai-Sun Wong, Yuichiro Eguchi, Manuel Romero-Gomez, Nahum Mendez-Sanchez, Ajay Duseja, Caglayan Keklikkiran, Jacob George, Elisabetta Bugianesi, Ashwani K. Singal, Saeed S Hamid, Khalid Aida Alswat, Wah Kheong Chan, Jian-Gao Fan, George A Papandreou, Stuart C. Gordon, Mohamed El Kassas, Stuart Roberts, Brian P. Lam, Andrei Racila, Linda Henry, Saleh Alqahtani, Maria Stepanova.
- In Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Clinically Significant Pruritus is Associated with High Serum Bile Acid (BA) Level and Advanced Fibrosis (AF), Zobair M Younossi, James M. Estep, Sean C. Felix, BP. Lam, Sumanta Mukherjee, Brandon Swift, Linda Casillas, Andrea Ribeiro, Jake Hunnicutt, Megan Mclaughlin, A Racila, Fatema Nader, Maria Stepanova
- Development and validation of CLDQ-MASH: a disease specific health related quality of life instrument for patients with metabolic dysfunction-associated steatohepatitis (MASH), Zobair M. Younossi, Maria Stepanova, Issah Younossi, Andrei Racila.
- Assessments of health utilities in patients with metabolic dysfunction-associated steatohepatitis (MASH): cross-walk between CLDQ-NASH, SF-6D, and the EuroQol EQ-5D, Zobair M Younossi, Maria Stepanova, Jesse Fishman, James Dodge, Dominic Labriola, Rebecca A Taub, Fatema Nader.